Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Abingdon Health PLC ( (GB:ABDX) ) has provided an update.
Abingdon Health PLC has been awarded £800,000 as part of a €5 million project funded by UK Research and Innovation to develop a rapid diagnostic test for Plasmodium vivax malaria. This project, part of a collaboration with prestigious institutions like the Institut Pasteur, aims to facilitate malaria control in sub-Saharan Africa by developing a point-of-care test that will be manufactured in Senegal, thereby enhancing local healthcare infrastructure and addressing WHO’s diagnostic needs.
More about Abingdon Health PLC
Abingdon Health PLC is a leading med-tech contract service provider based in York, England. The company specializes in developing, manufacturing, and distributing rapid tests, offering lateral flow product development, regulatory support, technology transfer, and manufacturing services for infectious diseases, clinical testing, and other areas. They also provide a range of regulatory services to the in vitro diagnostic and medical device industries, and their e-commerce platform, Abingdon Simply Test, offers self-tests for consumers.
YTD Price Performance: 0.0%
Average Trading Volume: 161,482
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £15.01M
Find detailed analytics on ABDX stock on TipRanks’ Stock Analysis page.
